Holen Sie sich die Stockscreener-App
0.2731
3.04%
0.00805
Schlusskurs vom Vortag:
$0.265
Offen:
$0.265
24-Stunden-Volumen:
6,386
Relative Volume:
0.03
Marktkapitalisierung:
$3.49M
Einnahmen:
$1.85M
Nettoeinkommen (Verlust:
$-5.56M
KGV:
-0.3601
EPS:
-0.7583
Netto-Cashflow:
1W Leistung:
-12.79%
1M Leistung:
-41.89%
6M Leistung:
-84.08%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.265
$0.2799
1-Wochen-Bereich:
$0.2585
$0.3131
52-Wochen-Spanne:
$0.2585
$50.00
20 20 Biolabs Inc Stock (AIDX) Company Profile
Firmenname
20 20 Biolabs Inc
Sektor
Branche
Telefon
(240) 453-6339
Adresse
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.2731 | 3.49M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
98.69 | 170.77B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.41 | 119.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.99 | 113.15B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.16 | 64.01B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.72 | 50.56B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc Aktie (AIDX) Neueste Nachrichten
20/20 BioLabs CEO on the Gaithersburg biotech's February stock market debut - Bethesda Magazine
A New York summit will host one-on-one meetings between 20/20 BioLabs executives and investors. - Stock Titan
20/20 BioLabs Inc Share PriceAIDX, RNS News, Articles, Quotes, & Charts (NASDAQ:AIDX) - Proactive financial news
20/20 BioLabs Inc Share PriceAIDX, RNS News, Articles, Quotes, & Charts (NASDAQ:AIDX) - Proactive Investors
20/20 Biolabs Hit With Nasdaq Deficiency Notice Over $2.5 Million Equity Shortfall - minichart.com.sg
20/20 Biolabs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
20/20 Biolabs outlines FDA engagement, Medicare reimbursement pathway and commercial gains - TradingView
20/20 BioLabs says its cancer blood test hit record quarterly revenue - Stock Titan
20/20 Biolabs (AIDX) Holds Above $0.60 Support After Modest GainDefined Outcome ETF - dars.gov.et
20/20 Biolabs (AIDX) Holds Above $0.60 Support After Modest GainPut Dominated - dars.gov.et
AIDX Q2 2026 Earnings: EPS Misses by 104% as Losses DeepenEarnings Analysis - vinanet.vn
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - Barchart.com
20/20 BioLabs to Discuss Record Q2 OneTest Revenue, Next Generation Dx Summit Takeaways and Commercial Strategy at September 2 Webinar - Quiver Quantitative
20/20 BioLabs reschedules investor webinar to 2 pm ET on Sept 2 - scanx.trade
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - Yahoo Finance
AIDX | 20/20 Biolabs, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
20/20 Biolabs, Inc. Common Stock (NASDAQ: AIDX) Stock Price, News & Analysis - kalkine.ca
20/20 (AIDX) Update: Records a 1.45% Decrease to $0.51 at the Close; Price Context: the Near-Term Reference Band Stretches From $0.48 to $0.54 at the CloseMcClellan Oscillator - vinanet.vn
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com Nigeria
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com South Africa
20/20 Biolabs adjourns vote on charter amendment, elects directors at annual meeting - Investing.com
20/20 Biolabs adjourns vote on charter amendment, elects directors at annual meeting - Investing.com India
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com Canada
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com India
20/20 Biolabs adjourns vote on charter amendment, elects directors at annual meeting - Investing.com
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com UK
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - Sahm
20/20 Biolabs Q2 Results: EPS misses, revenue up 36% - scanx.trade
20/20 Biolabs Releases Q2 2026 Financial Results - AlphaStreet
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - The Manila Times
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - Yahoo Finance
20/20 BioLabs Reports Second Quarter 2026 Financial Results - GlobeNewswire
20/20 Biolabs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
20/20 Biolabs, Inc. Common Stock (NASDAQ: AIDX) Stock Price, News & Analysis - Kalkine
20/20 Biolabs to host investor webinar; reports best quarterly cancer-test revenue to date - tradingview.com
After Taipei, Tokyo and Seoul, 20/20 BioLabs to discuss deal options - Stock Titan
20/20 BioLabs sets Aug 5 webinar on East Asia roll-up strategy - scanx.trade
20/20 BioLabs meets potential partners in East Asia - Investing.com
20/20 BioLabs meets potential partners in East Asia By Investing.com - Investing.com Canada
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy - The Manila Times
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets - GlobeNewswire
20/20 Biolabs (AIDX) Shares Slide 8.35% as Stock Tests Critical Support at $0.43High Yield Stocks - vinanet.vn
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Slides 4.1% as Stock Tests Key Support at $0.47Large Cap Trends - dars.gov.et
Rokit Healthcare, US 20/20 BioLabs to Co-Develop AI Multi-Cancer Prediction Platform - Seoul Economic Daily
20/20 BioLabs enters standstill pact on preferred stock - Investing.com
20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions - Quiver Quantitative
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - The Manila Times
Press Release: 20/20 BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Series E Convertible Preferred Stock - Moomoo
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - Yahoo Finance
Finanzdaten der 20 20 Biolabs Inc-Aktie (AIDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
8.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):